MedTrace Logo

Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control

NCT06667037 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2025-02-26

No results posted yet for this study

Summary

The purpose of this multicenter randomized clinical trial is to evaluate the myopia control effect of orthokeratology and 0.01% atropine sequential treatment in children and adolescents, as compared to continuous treatment with orthokeratology.

Conditions

  • Myopia

Interventions

DEVICE

Ortho-k lenses

Ortho-k lenses will be administered nightly.

DRUG

0.01% Atropine

0.01% Atropine will be administrated twice a day with an interval of about 12 hours. Drop into the conjunctival sac and immediately compress the lacrimal sac of the inner canthus for 2-3 minutes.

Sponsors & Collaborators

  • People's Hospital of Guangxi

    collaborator UNKNOWN

  • Henan Provincial People's Hospital

    collaborator UNKNOWN

  • Tianjin Medical University Eye Hospital

    collaborator OTHER

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-21
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06667037 on ClinicalTrials.gov